Amlodipine/valsartan/hydrochlorothiazide - Novartis

Drug Profile

Amlodipine/valsartan/hydrochlorothiazide - Novartis

Alternative Names: Copalia HCT; Dafiro HCT; Exforge HCT; Imprida HCT

Latest Information Update: 19 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Benzothiadiazines; Branched-chain amino acids; Dihydropyridines
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 25 Aug 2018 Adverse events data from a phase III trial in Hypertension presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2018)
  • 03 Dec 2014 Launched prior to this date for Hypertension in Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Netherlands, Poland, Spain, Switzerland, Australia, Norway, Turkey, Malaysia, Singapore, Thailand and Hong Kong (PO)
  • 01 Dec 2014 First generic equivalent available in USA for Hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top